Genmab GMAB

Nasdaq · Pharmaceutical Preparations
$50.60−1.46%Nov 20 close · Databento
Every report →
TradingView’s own chart and price feed. The page’s numbers are end-of-day closes.

Data provided by Databento (end of day). Next close = the first close after a story against the close before it; official daily closes only, not a call, not advice.

The numbers

fiscal 2024, as filed with the SEC · 66-metric EOD snapshot via Databento
Revenuekr 21.5B +30.7%
True FCF (ex-SBC)kr 7.6B +8.1%
Rule of 4065.9%
ROIC19.7%
FCF Margin35.2%
EPS, dilutedkr 121.36 +83.8%
Modern Valuation (EOD)
Market Cap—
Enterprise Value—
EV / True FCF—
EV / FCF—
EV / Gross Profit—
EV / EBIT—
EV / Sales—
P / E (GAAP)—
P / FCF—
P / Oper. CF—
P / Book—
Owner & Cash Yields
True FCF Yield—
FCF Yield—
Owner Earn. Yield—
Earnings Yield—
Shareholder Yield—
Buyback Yield—
Dividend Yield—
Dividend / sh—
Payout Ratio—
FCF / sh—
EPS (diluted)kr 121.36
Compounder & Returns
Rule of 4065.9%
ROIC19.7%
Cash ROIC (CROIC)28.3%
GP / Assets—
ROE21.4%
ROA17.1%
Gross Margin—
Oper. Margin31.1%
Net Margin36.4%
FCF Margin35.2%
True FCF Margin35.2%
Quality & Dilution
Cash Conversion97%
Accrual Ratio+0.2%
SBC % of FCF—
SBC % of Rev—
Reinvest. Rate128%
Sales Growth Y/Y+30.7%
Sales 3Y CAGR+36.8%
EPS Growth Y/Y+83.8%
FCF Growth Y/Y+8.1%
FCF 3Y CAGR+56.6%
Share Change Y/Y—
Balance Sheet & Scale
Revenue (FY)kr 21.5B
Gross Profit (FY)—
Oper. Income (FY)kr 6.7B
GAAP Net Incomekr 7.8B
True FCF (ex-SBC)kr 7.6B
Cash & Equivkr 9.9B
Total Debt—
Net Cash (Debt)kr 9.9B
Net Cash % MCap—
Debt / FCF (yrs)—
Current Ratio5.25
Price & Technicals (EOD)
Perf Week−1.50%
Perf Month+26.50%
Perf Quarter+53.24%
Perf Half Y+88.31%
Perf YTD+83.87%
SMA 20 Dist−4.11%$52.77
SMA 50 Dist+17.72%$42.98
SMA 100 Dist+36.97%$36.94
Window High−11.68%$57.29
Window Low+112.16%$23.85
RSI (14) · Vol55.297%v
Income Distribution & Cash Flow ConversionHow every dollar of GMAB revenue flows through cost of goods, operating expenses, taxes, GAAP net income, and dilution-adjusted free cash flow
REVENUE · 100%kr 21.5BGROSS PROFIT · 95.4%kr 20.5BCOST OF REV · 4.6%kr 985.0MOPER. INCOME · 31.1%kr 6.7BOPEX · 64.3%R&D kr 9.7B · SG&A kr 3.8BNET INCOME · 36.4%kr 7.8B
Where Every kr 100 of Revenue Goes (FY2024)
Cost of Revenue (COGS)kr 985.0M (kr 4.6 / kr 100)
R&D Reinvestmentkr 9.7B (kr 45.3 / kr 100)
SG&A & Other OpExkr 4.1B (kr 19.0 / kr 100)
Tax & Non-Operatingkr 0 (kr 0.0 / kr 100)
Net Profit Keptkr 7.8B (kr 31.1 / kr 100)
Earnings Quality: GAAP Profit → True Owner Cash (FY2024)
GAAP Net Incomekr 7.8B (36.4% margin)
Operating Cash Flow (OCF)kr 7.8B(36.1% of rev)
Less: Capital Expenditures−kr 187.0M(0.9% of rev)
Standard Free Cash Flow (FCF)kr 7.6B(35.2% margin)
Less: Stock-Based Comp (SBC)—
True FCF (Owner Cash ex-SBC)kr 7.6B(35.2% of rev)

Operating leverage — margins

GrossOperatingNet
0%40%80%31%36%FY20FY21FY22FY23FY24
Unlocked SEC EDGAR Accounting Statements (DKK)All 3 statements · Common-size (% of Revenue / Assets) · YoY growth · Tap any core row to explain
Line Item (DKK)FY2020FY2021FY2022FY2023FY2024YoY Δ4Y CAGRTrend
Income Statement
Cost of Revenue (COGS)———kr 226.0Mkr 985.0M+335.8%+335.8%
Research & Development (R&D)kr 3.1Bkr 4.2Bkr 5.6Bkr 7.6Bkr 9.7B+27.8%+32.8%
Selling, General & Admin (SG&A)kr 661.0Mkr 1.3Bkr 2.7Bkr 3.3Bkr 3.8B+15.0%+54.7%
Interest Expensekr 1.6Bkr 702.0Mkr 2.5Bkr 1.6Bkr 2.0B+21.7%+6.1%
Income Tax Expensekr 1.1Bkr 961.0Mkr 1.5Bkr 1.3Bkr 1.3B+2.7%+3.6%
Balance Sheet
Cash & Equivalentskr 7.3Bkr 9.0Bkr 9.9Bkr 14.9Bkr 9.9B−33.7%+7.9%
Inventorykr 62.0Mkr 62.0Mkr 62.0Mkr 57.0Mkr 62.0M+8.8%+0.0%
Total Current Assetskr 18.8Bkr 22.6Bkr 28.2Bkr 33.1Bkr 27.9B−15.9%+10.3%
Total Assetskr 21.1Bkr 24.5Bkr 30.1Bkr 35.3Bkr 45.8B+29.8%+21.3%
Total Current Liabilitieskr 1.3Bkr 1.6Bkr 1.8Bkr 2.5Bkr 5.3B+113.7%+43.5%
Total Liabilitieskr 2.0Bkr 2.4Bkr 2.8Bkr 3.7Bkr 9.1B+147.7%+45.7%
Stockholders' Equitykr 19.1Bkr 22.1Bkr 27.3Bkr 31.6Bkr 36.7B+16.1%+17.7%
Net Cash / (Net Debt)kr 7.3Bkr 9.0Bkr 9.9Bkr 14.9Bkr 9.9B−33.7%+7.9%
Invested Capitalkr 11.9Bkr 13.2Bkr 17.4Bkr 16.7Bkr 26.8B+60.3%+22.6%
Cash Flow & Capital Allocation
Depreciation & Amortization (D&A)kr 79.0Mkr 110.0M——kr 110.0M—+8.6%
Capital Expenditures (CapEx)kr 307.0Mkr 252.0Mkr 317.0Mkr 366.0Mkr 187.0M−48.9%−11.7%
True FCF (ex-SBC Owner Cash)kr 6.1Bkr 2.0Bkr 3.6Bkr 7.0Bkr 7.6B+8.1%+5.5%

Fundamentals, income distribution and multi-year statements from SEC EDGAR filings (public domain). Valuation multiples, performance and technicals computed from Databento 1D EOD closes. For information only, not investment advice.

On the Wire

what GMAB did at the next close after each story
The Wire at 7 AM ET, free. Top stories with a bull and a bear case on each, every morning. No account needed.